Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.
Reykjavik, Iceland-based Alvotech has partnered with Cipla Medpro to bring 5 biosimilar candidates to South Africa.
The portfolio will include 2 biosimilar candidates for oncology and 3 for autoimmune diseases; however, the 5 molecules that the biosimilars will reference were not publicly disclosed.
Alvotech will be in charge of development and supply of the products and Cipla will be responsible for commercialization and regulatory registration.
“We’re delighted to establish this important partnership with Cipla…an ideal commercial partner, with a leading presence in the South African pharmaceutical market,” Mark Levick, CEO of Alvotech, said in a statement.
Alvotech’s Other Partners
Alvotech does not have any biosimilars approved yet, but it has been setting other deals for biosimilar distribution with diverse business partners, possibly involving the same biosimilar candidates but in different geographic areas.
In September 2020, Alvotech extended its partnership with DKSH to include distribution of multiple biosimilar products in Asia, the United States, and Europe. Alvotech said this would involve distribution of an adalimumab biosimilar candidate (AVT02).
In August 2020, Alvotech announced a partnership with Teva Pharmaceuticals to commercialize 5 biosimilar candidates for the US market.
Additionally, Avotech has a partnership with JAMP Pharma to market 5 biosimilar candidates in the Canadian market and with Kamada for 6 biosimilar candidates in the Israeli market.
Except for AVT02, Alvotech and its partners have not disclosed any of the molecules included in the deals and there is no information on whether any of the candidates are the same between the deals.
More on Cipla Medpro
Cipla Medpro was founded in South Africa in 1995 under the name Enaleni Pharmaceuticals. Cipla Medpro mostly focuses on over-the-counter and generic medications.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.